Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/220011
Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: the NOBROLA phase 2 study
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Purpose: To evaluate olaparib in advanced triple negative breast cancer (TNBC) patients with homologous recombination deficiency (HRD) and no germline BRCA1/2 mutations (gBRCA1/2mut). Methods: NOBROLA (NCT03367689) is a single-arm, open-label, multicenter, phase IIa trial, enrolling adult patients with advanced TNBC without gBRCA1/2mut and with HRD, who were treated with olaparib. The primary endpoint was clinical benefit rate (CBR) per RECIST v.1.1. Results: Six of 114 patients were eligible and received olaparib. Median follow up was 8.5 months. CBR and overall response rate (ORR) were 50 % (95 % CI, 11.8-88.2). Conclusions: The observed results could prompt further investigation. Trial: ClinicalTrials.gov identifier NCT03367689.
Matèries
Matèries (anglès)
Citació
Citació
CORTÉS, Alfonso, LÓPEZ MIRANDA, Elena, FERNÁNDEZ ORTEGA, Adela, CARAÑANA, Vicente, SERVITJA, Sonia, URRUTICOECHEA RIBATE, Ander, LEMA ROSO, Laura, MÁRQUEZ, Antonia, LAZARIS, Alexandros, ALCALÁ LÓPEZ, Daniel, MINA, Leonardo, GENER, Petra, RODRÍGUEZ MORATÓ, Jose, ANTONARELLI, Gabriele, LLOMBART CUSSAC, Antonio, PÉREZ GARCÍA, José manuel, CORTÉS, Javier. Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: the NOBROLA phase 2 study. _The Breast_. 2024. Vol. 78. [consulta: 7 de febrer de 2026]. ISSN: 0960-9776. [Disponible a: https://hdl.handle.net/2445/220011]